DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...
DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical partn ...
Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.
The global market is estimated at USD 25,900.5 million in 2025 and is forecast to reach USD 64,187.5 million by 2035, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback